Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications By Berthony Deslouches, Y. Peter Di Published in: Oncotarget DOI: 10.18632/oncotarget.16743 ABSTRACT In the last several decades, there have been significant advances in anticancer therapy. However, the development of resistance to cancer drugs and the lack of specificity related to actively dividing cells leading to toxic side effects have undermined these achievements. As a result, there is considerable interest in alternative drugs with novel antitumor mechanisms. In addition to the recent approach using immunotherapy, an effective but much cheaper therapeutic option of pharmaceutical drugs would still provide the best choice for cancer patients as the first line treatment. Ribosomally synthesized cationic antimicrobial peptides (AMPs) or host defense peptides (HDP) display broad-spectrum activity against bacteria based on electrostatic interactions with negatively charged lipids on the bacterial surface. Because of increased proportions of phosphatidylserine (negatively charged) on the surface of cancer cells compared to normal cells, cationic amphipathic peptides could be an effective source of anticancer agents that are both selective and refractory to current resistance mechanisms. We reviewed herein the prospect for AMP application to cancer treatment, with a focus on modes of action of cationic AMPs. INTRODUCTION Despite unprecedented successes in the field of medicine in the last fifty years, cancer remains a serious threat to human survival [1–4]. Chemotherapeutics, in combination with or in addition to surgery and radiotherapy, play an important role in increasing life expectancy of cancer patients [5–9]. Tumors are clones of rapidly dividing cells unregulated by normal mechanisms of growth suppression. Chemotherapy aims at interfering with this uncontrolled process of cell division [10, 11]. However, many cancer drugs typically lack specificity to transformed cells [12–14]. Consequently, they also kill healthy cells undergoing rapid proliferation resulting in toxic side effects. Another limitation of chemotherapy is the development of resistance by tumor cells [15–17]. Thus, a more effective alternative could be other classes of drugs with the property to specifically target cancer cells without toxicity to normal cells. One more requirement is a lower tendency for development of resistance against such drugs compared to conventional chemotherapeutics. AMPs are an untapped resource with low propensity to elicit development of resistance by its target and to display toxicity to healthy cells undergoing rapid proliferation [18–20]. AMPs are an essential component of the host innate immunity [21–23]. Although they display considerable diversity in both primary and secondary structures, [24–27] the cationic amphipathic motif is a typical structural feature of AMPs and an important determinant of antimicrobial functions [28–31]. While AMP investigations have been largely focused on antimicrobial properties, there is increasing evidence that AMPs display antitumor functions, perhaps in the context of a multifunctional host defense system of multicellular organisms. Alternatively, the antitumor property could be a “side-activity” not necessarily implicated in the natural selection of the common cationic amphipathic structure of AMPs. We reviewed herein the potential of AMPs for application to antitumor therapy as anticancer peptides (ACPs) with novel mechanisms. Broad structural and functional properties of AMPs not pertaining to selective action against cancer cells and antitumor efficacy are reviewed elsewhere [32–39]. Basis for antitumor property of AMPs: selective recognition of cancer cells via electrostatic interactions Most AMPs are short (typically 10 to 50 residues long) cationic peptides with an amphipathic structure [40–48]. They are structurally diverse in both amino acid compositions and secondary structures (α-helix, β-sheets, extended helix, and loop) (Figure 1). There are multiple reviews of AMP structures, [49–52] which we do not discuss here. AMPs generally recognize their target via electrostatic interactions with negatively charged lipids on cell membranes [53–56]. Because these interactions are not mediated by specific receptors, conversion of L to D enantiomers does not necessarily disrupt the binding capacity of AMPs as shown by Papo and others [57–59]. AMPs display strong interactions with bacterial membranes due to high density of electronegative charges on the bacterial surface, such as lipopolysaccharide (LPS) on the outer membrane of gram-negative bacteria [60–63] or lipoteichoic acid (LTA) on gram-positive bacterial membranes [64–68]. Of note, there is no consensus sequence for binding activities, as cationic AMPs (typical charge of +2 or more) of all types of secondary structures (α-helix, β-sheets, loop alone or in combination; Figure 1) and diverse primary sequences with different positive charges are able to recognize their microbial targets [69–73]. It is, therefore, evident that the cationic amphipathic motif is the main requirement for activity whereas the primary sequence determines specificity or spectrum of activity. While AMPs may display toxicity to mammalian cells, toxic concentrations are commonly one log of magnitude higher compared to minimum inhibitory concentrations against bacteria [74, 75]. Hence, it is logical to predict that AMPs with promising pre-clinical data will display a minimum therapeutic index (maximum tolerated dose/minimum therapeutic dose) required for efficacy in specific applications. [Figure: Main structural classes of cationic antimicrobial peptides (AMPs)] Some AMPs specifically target tumor or cancer cells because transformed cells generally incorporate phosphatidylserine (PS, 3–9% of the total amount of phospholipids) in the outer leaflet of the plasma membrane (Figure 2) [76–78]. PS is usually found on the inner leaflet of the cytoplasmic membrane of normal mammalian cells. However, it can be transferred to the outer leaflet of the plasma membrane of cells undergoing apoptosis, which disrupts the asymmetry observed for normal mammalian cell membranes [79, 80]. Hence, this change in asymmetry is typically shared by both apoptotic cells and several types of cancer cells and facilitates recognition and clearance of these cells by monocytes [81–83]. Other factors that may contribute to elevated negative charges on cancer cells include heparin sulfates, [84–86] and O-glycosylated mucins on the surface of tumor cells [87–90]. However, the density of electronegative charge (due to a single phosphate group on PS) on cancer cells is relatively lower compared to negative charges (due to multiple phosphate groups on LPS, LTA, in addition a phosphate group on PS) on bacterial cell membranes. As a result, AMP affinity for cancer cells is inherently weaker than the affinity for bacteria. Of note, electronegative charges do not always enhance activity. As shown by Fadnes et al. (2009), Cell surface heparin sulfate inhibits the bovine AMP lactoferricin by sequestering the peptide away from the lipid membrane [91]. Cancer cell membranes display other properties that may facilitate killing by AMPs compared to normal cell membranes. Some transformed cells may incorporate lower levels of cholesterol in their membranes, enhancing fluidity. For instance, cell membranes of human leukemia and lung cancers display increased fluidity due to a lower level of cholesterol in their membranes compared to membranes of normal leukocytes and pulmonary cells [92–94]. This increase in membrane fluidity may potentiate lytic effects of AMPs as in the case of cecropins and other peptides [95–97]. Conversely, some cancer cells incorporate elevated cholesterol levels as part of lipid rafts (e.g., prostate cancer) in their membranes compared to normal cell membranes [98, 99]. Therefore, the role of cholesterol content in cationic ACP activity against cancer cells remains unclear. For instance, some enveloped viruses are susceptible to AMPs (e.g., LL37 activity against herpes simplex and influenza viruses) although they incorporate high cholesterol content (lipid rafts) in their membranes [100, 101]. Another interesting property of cancer cells, which may enhance AMP binding, is the increase in surface area with increasing number of microvilli [102, 103]. Upon binding to cancer cells, AMPs may either disrupt the membrane or penetrate the cell and attack the mitochondria leading to apoptosis. The defensins (29–45 amino acids long), an important class of Cys-rich antimicrobial peptides (β-sheets, Figure 1), were among the first AMPs to be discovered and to demonstrate antitumor activity. Although these AMPs have been isolated from different species including plants, [104, 105] the α-(Cys1-Cys6, Cys2-Cys4 and Cys3-Cys5 bridges, with Cys residues numbered based on location from the N-terminus) and β-defensins (Cys1-Cys5, Cys2-Cys4 and Cys3-Cys6 bridges) synthesized in humans are the most studied defensins to date [104–109]. Antitumor activities of α-defensins, notably the human neutrophil peptides (HNP) 1–3, have been demonstrated via both membranolytic and apoptotic mechanisms as well as inhibition of neovascularization required for tumor growth [110, 111]. However, the HNPs also kill normal cells such as fibroblasts, epithelial cells, and leucocyte. Similarly, the plant defensins also display a lack of selectivity towards tumor cells [112–115]. As a result, the defensins are generally not efficient ACP therapeutics, or they require structural optimization to achieve antitumor selectivity. We examined hereafter the antitumor properties of AMPs derived from animals based on two sets of mechanisms, selective plasma membrane disruption or non-membranolytic cytotoxicity. [Figure: Common antitumor mechanisms of cationic AMPs classified as ACPsACPs (anticancer peptides), or cationic AMPs with anticancer properties, selectively recognize cancer cells by electrostatic interactions with negatively charged phospholipids on the surface of eukaryotic cells [e.g., PS (phosphatidylserine)]. Some ACPs demonstrate in vivo efficacy (e.g., *MGB2, Gomesin, K6L9, LTX-315); ACPs tend to kill cancer cells by membrane perturbation (blue/cyan), although some (e.g., KLA, Pardaxin) may penetrate the target cell and disrupt the mitochondrial membrane resulting in apoptosis (green/purple). (How?), mechanism unclear; brown perpendicular bar, inhibition; CTL, cytotoxic T-Lymphocytes; M, mitochondria, SER, smooth endoplasmic reticulum; RER, rough endoplasmic reticulum; R, ribosomes; N, nucleus; V, vacuole; L, lysosome; only cholesterol and other lipids are shown; membrane proteins are omitted for clarity.] Evidence for selective membrane disruption One of the earliest indications that AMPs may be a source of anti-tumor therapy is a study by Cruciani and colleagues [116]. Discovered by Michael Zasloff, the magainins are a family of AMPs with broad-spectrum antibacterial activity found in the African frog Xenopus larvae [117–119]. Cruciani et al. showed that magainin 2 and its analogues demonstrated activity selectively against both hematopoietic and solid tumor cells. The cytotoxic effects of the magainins were rapid (within 1 hour) at a concentration as low at 12 μg/mL and were not observed against normal lymphocytes even at up to 200 μg/mL. The peptides induced ion channels leading to leakage of Na+, K+, and Cl− ions. The cytotoxic effects of the peptides were abrogated when the electrical gradient was eliminated prior to peptide exposure, indicating the membrane potential is essential to the peptide activity. Exposure of the mitochondria to the peptide resulted in inhibition of respiration and leakage of glucose through the peptide-induced channels [120]. Subsequently, an interesting link was established between two independent discoveries [the Cecropins (insect) and magainins (frog)] by Boman and Zasloff, respectively [119, 121, 122]. In this study a hybrid between Cecropin A and magainin 2 (CA-MA-2, KWKLFKKI-P-KFLHSAKKF-NH2) was constructed with three more derivatives based on proline substitutions in the hinge region [123]. These investigators discovered that the activities against several tumor cell lines were enhanced compared to toxicity to erythrocytes and primary fibroblasts. The cationic peptide CA-MA-2 displayed no detectable hemolysis and cytotoxicity against the primary cell NIH-3T3 fibroblast at concentrations up to 100 μM. In contrast, the 50% inhibition concentration (IC50) against several tumor cell lines was as low as 20 μM. it is important to note that antimicrobial activity was always higher than the anti-tumor effects, suggesting that these AMPs could be further optimized specifically for enhanced antitumor properties. Disruption of large phosphatidylcholine (PC)/phosphatidylserine (PS)-based unilamellar (mixed PC-PS) vesicles by CA-MA-2 indicated a membrane perturbation mechanism, although it would have been informative for the investigators to include the parent peptides Cecropin A and Magainin 2 in this study. Another example of cell membrane disruption was more directly demonstrated by the AMP chrysophsin-1 (FFGWLIKGAIHAGKAIHGLI) [124]. Using fluorescent, scanning and transmission electron microscopy, combined with LDH release, the investigators showed convincingly that the cationic amphipathic peptide disrupted the plasma membrane of several cancer cell lines at much lower concentrations compared to the CA-MA-2 peptide. Cancer cell death by apoptosis was ruled out as caspase expression and activities were not affected by chrysophsin-1. While these previous studies show great promise, they fell short of demonstrating anti-tumor efficacy in vivo. In addition, AMP activity against cancer cells is much lower than their antimicrobial activity. Hence, two main problems remained to be addressed: (1) the limited anti-tumor activity and (2) specificity toward tumor cells. Both limitations can be overcome if the specificity of AMPs towards tumor cells is enhanced. The strength of AMP interaction with cancer cells may affect both activity and specificity. Hence, in 2011 Liu and colleagues published an elegant study addressing this limitation. They reasoned that linking an AMP to a cancer-homing peptide would enhance specificity and activity against cancer cells. Isolated from frog skin, Bombesin appeared to be a good candidate as the 14-residue peptide recognizes a variety of human cancer cells. The question was which AMP would be the best choice for this experiment? Magainin II (MG2), also derived from frog skin, was one of the most studied AMPs at the time. In fact, the magainins are likely to become the first classical family of AMPs to be used clinically as the derivative pexiganan (cream, 0.08%) is currently in phase III clinical trials in patients with mild infections of diabetic foot ulcers [125–127]. Hence, MG2 was linked to Bombesin (MG2B, GIGKFLHSAKKFGKAFVGEIMNSGG-QRLGNQWAVGHLM). The MG2B peptide displayed higher cytolytic effects compared to MG2. In fact, the in vivo efficacy of MG2B was demonstrated in mice bearing MCF-7 tumor grafts. With a daily intratumoral injection of MG2B (20 mg/kg) for 5 days, there was a significant reduction of the tumor size in mice [128]. There are several other examples of membranolytic effects of ACPs, including the use of the ACP gomesin (ZCRRLCYKQRCVTYCRGR) in a cream formulation for successful topical treatment in mice [129, 130]. Importantly, one of the most significant anti-cancer effects of a membranolytic ACP was demonstrated by Papo and colleagues (Figures 2 and 3) [131–133]. The investigators constructed a D-enantiomer of an engineered ACP K6L9. With a daily dose of the peptide (9 mg/kg) injected systemically every other day for a total of nine doses, immunodeficient mice implanted with both breast and prostate metastatic cancers were protected against malignant disease. The tumors became necrotic, and the density of the tumor-induced neovascularization was significantly reduced. The selective binding of the ACP to the negatively charged PS and cytoplasmic membrane depolarization were also demonstrated. The ACP D-K6L9 (LKLLKKLLKKLLKLL) is the most successful demonstration of the systemic anticancer efficacy of an ACP to date [58]. Notably, D-K6L9 is made of only two amino acids. As natural AMPs work in the context of a multifunctional immune system, they are more efficient at protecting the host against disease than they are at curing established illnesses (more preventive than therapeutic). Hence, it is logical to engineer AMPs with more optimized structures for therapeutic applications as opposed to using AMPs as they are produced in nature. We predict that the success of AMP engineering will be facilitated by the establishment of a definitive framework for distinguishing the unique role of the cationic from that of the hydrophobic domain in selectivity toward the target versus host cells. Once a guideline for selective killing of different target cells is established, it will then be possible to design AMPs with enhanced therapeutic index with less trial and error. In the case of the peptide K6L9, the investigators use the principle of amphipathicity to design a 15-residue AMP (charge = +6) with an idealized amphipathic helix (Figure 3). In addition, the use of D-amino acids enhances stability, addressing a concern for lability of AMPs [58, 132–134]. This is an important example of how AMP engineering can lead to enhanced results. Yet, the most advanced (in terms of clinical trials) cationic ACP is not D-K6L9. Over the last two decades, there has been an increasing interest in bovine lactoferricin (LFcinB). LFcinB is derived from the natural milk protein bovine lactoferrin (LFB) by pepsin digestion [135–139]. In addition to its antimicrobial properties, [140–143] LFcinB demonstrates enhanced activities against cancer cells compared to normal mammalian cells [139, 144, 145]. Importantly, high-resolution imaging revealed a membranolytic mechanism [146]. These studies reached a turning point when Eliassen and colleagues (2006) began to examine the in vivo efficacy of LFcinB in mice, demonstrating the growth inhibition of neuroblastoma xenografts [147]. While the peptide could be localized in the mitochondria with caspase activation, the lytic effects on the cytoplasmic membrane represented the primary cytotoxic mechanism, as pan-inhibition of the caspase enzymatic cascade could not reverse the cytotoxic effects of the peptide. These studies led to further structural optimization using 3,3-diphenylalanine (Dip) substitutions for Trp at specific positions of the 9-mer template. These investigations resulted in enhanced selectivity (IC50 below 5–10 μM) against a variety of tumors compared to normal cells. More importantly, these studies revealed a cytolytic-immunogenic dual cell death mechanism [148–156]. Lysis of the tumor induced the release of danger-associated molecular patterns (DAMPs) including high mobility group box protein 1 (HMGB1, reviewed by Frank et al., 2015 [157]) in addition to antigens from the dead tumor cells. As potent stimulators of immune responses, HMGB1 potentiated A20 lymphoma-specific activation of immature dendritic cells with subsequent generation of tumor-specific cytotoxic T-lymphocytes and tumor cell lysis. The immunogenic cell death was further confirmed by the adoptive transfer of syngeneic A20 lymphoma-specific CTLs and resulting protection of immunodeficient mice from tumor implants. Further, LTX-315-treated mice in remission from the tumor were protected from a second challenge by the syngeneic tumor and not by a different tumor type, indicating the specificity of the immunogenic cell death. Hence, the potent derivative LTX-315 was selected for advanced preclinical studies. LTX-315 is now (2016) in phase 1 clinical trial as described later. The study of LTX-315 is yet another illustration of how natural AMPs can be optimized for specific clinical applications. [Figure: Helical wheel analysis of the engineered AMP K6L9 designed by Papo et al. [57]The peptide was modeled to form an idealized amphipathic helix with only two amino acids; a structural optimization strategy that has been shown to enhance antimicrobial functions, now applied to antitumor properties as well. Arrow indicates direction of the hydrophobic moment. Structural motifs: yellow, hydrophobic; blue, cationic.] Non-membranolytic mechanisms of ACP The ACP K6L9, while exerting a direct membranolytic effect on cancer cells, demonstrates anti-angiogenic and anti-metastatic effects, an anti-tumor mechanism that remains to be elucidated. Another common anti-cancer mechanism is the potentiation of apoptosis in cancer cells by ACP [158–160]. While ACPs selectively interact with cancer compared to normal cell membranes, some AMPs may both perturb the membrane and penetrate the cells while other non-lytic ACPs may simply traverse the membrane and access the intracellular compartment. In both cases, the ACP disrupts the mitochondria (as expected because of the bacterial origin of mitochondria) and induces programmed cell death. This apoptotic mechanism is demonstrated by swelling of the mitochondria, disruption of the mitochondrial membrane, translocation of PS to the surface of the cell, and stimulation of apoptotic markers (e.g., caspase enzymatic pathway). One of the earliest examples of an apoptotic ACP was reported by Mai et al., 2001 [161]. The authors used a KLA repeat AMP [(KLAKLAK)2] conjugated with a transduction peptide (RRQRRTSKLMKRGGKLAKLAKKLAKLAK) by a glycine pacer. The intratumoral injection of the chimeric ACP resulted in the translocation of the peptide into the cytoplasm of the tumor cells, disruption of the mitochondria, and stimulation of apoptotic enzymatic cascade by caspase 3 activation. Other ACPs have the inherent property to penetrate the cancer cells without the need for conjugation with a cell penetrating peptide. An example of such a peptide (GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE) is pardaxin, which induces apoptosis of squamous cell carcinoma cells by caspase 3 activation [162]. In addition, some AMPs may be used as cell penetrating peptides to transfer an anticancer drug into cancer cells. This is the case of the AMP PR39 (RRRPRPPYLPRPRPPPFFPPRLPP RIPPGFPPRFPPRFP) used as a cell penetrating peptide to transfer Stat3 siRNA (the cargo) into breast cancer cells [163–165]. As previously mentioned, another interesting antitumor mechanism is the immunogenic cell death conferring long-lasting protection against future challenges from the same tumor type. Such a mechanism is displayed by the ACP LTX-315, [151] which was selected for advanced preclinical studies. LTX-315 is now in phase 1 clinical trial [151, 155, 156]. Noteworthy is an antitumor mechanism occurring via the lysosomal-mitochondrial death pathway by the defensin Brevenin-2R (in vitro activity) [166]. As the anticancer mechanisms of AMPs become increasingly clear, structural optimization for enhanced anticancer potency will be more achievable and, therefore, clinical development more likely to succeed. Of note, AMPs synthesized in plants are another important source of peptide therapeutics that could be used as anticancer agents. However, for many of these AMPs, the anticancer mechanisms are unclear. AMPs derived from plants are beyond the scope of this review and are reviewed elsewhere [32]. A list of representative AMPs with selective antitumor mechanism is shown Table 1. [Table: Representative antimicrobial peptides with selective antitumor mechanisms] Prospect for clinical use of AMPs as anticancer agents The clinical development of AMPs as ACPs faces some of the same challenges to AMP clinical development as antimicrobial agents. AMPs are not traditional drugs. Because they have multifunctional properties, the adaptation from their natural environment to clinical applications without structural optimization is rather challenging. While AMPs work well in the context of a competent immune system, it is likely that in nature a particular AMP structure is not completely optimized for a single function (e.g., antibacterial, antiviral, or anticancer). The field also faces some unfounded criticisms that have hindered support for AMP development. Some of these criticisms are that (1) “AMPs are labile and likely to have poor pharmacokinetic properties”, an assumption based on the peptidic nature of AMPs; (2) “AMPs are expensive to make”; (3) “AMPs are not good drugs” because they do not recognize specific receptors. Although stability is an important concern, the first criticism is based on the assumption that all peptides have similar stability and clearance mechanisms. One of the shortcomings of AMPs is the lack of correlation between in vitro susceptibility testing and efficacy in animal models, with some exceptions including some of the AMPs discussed in this review and elsewhere [58, 156, 167–169]. Assays establishing correlation between in vitro stability and bioavailability in animal models might address this concern. Currently, AMPs with optimized structures are amenable to parenteral administration including systemic, respiratory, intramuscular, intraperitoneal, or subcutaneous unless otherwise contraindicated [167, 168, 170–172]. Although the peptidic nature of AMPs precludes oral delivery, the development of specific delivery systems protecting AMPs from degradation by digestive enzymes may increase intestinal absorption and the feasibility of oral administration. Several strategies can be used to enhance PK properties of AMPs. One approach is the utilization of D-enantiomers to increase stability, [133] although such strategy is only indicated if decreasing peptide clearance enhances therapeutic efficacy and does not potentiate toxic side effects. Other strategies include end-to-end cyclization, C-terminus amidation, pegylation [attachment of polyethylene glycol (PEG) to a molecule], and liposomal delivery. Cyclisation and amidation can confer peptide stability by decreasing susceptibility to protease digestion, as demonstrated by the modification of gomesin and other AMPs [173, 174]. As a principle, all AMPs used in our laboratory are amidated [18, 20, 175, 176]. As shown by the Gumbleton group and others, pegylation of AMPs can result in lower host toxicity without affecting antimicrobial activity [177]. Pegylation enhances the pharmacological properties of a given drug in a number of ways [178–183]. Because it increases hydrophilicity, PEG serves as a shield that protects against protease digestion, prolongs circulation time, and reduces the glomerular filtration rate. An interesting example of AMP pegylation is a recent design by Kelly et al., 2016 as shown in Figure 4 [183]. A pro-peptide was designed using the AMP P18 covalently attached to a linker region that is sensitive to the cysteine protease cathepsin B, followed by a PEG region to confer thermodynamic stability to the peptide. In vitro studies show that selectivity index can be enhanced against an ovarian carcinoma cell line (A2780). While this strategy is still conceptual, as it requires extensive in vivo studies for proof of concept, it shows how a pro-peptide can be designed in combination with pegylation to enhance the PK properties of an ACP or AMP. Another strategy could be the liposomal formulation of AMPs [184–187]. However, one shortcoming is that AMPs are membrane active and could, therefore, bind and disrupt the liposome. Packaging the molecule as an inactive pro-peptide in the liposome could theoretically overcome this problem. One last potential caveat is whether we are able to produce liposomes that can discriminate between the target and normal cells. An AMP delivered inside a eukaryotic cell will probably interact with mitochondria as it would with a bacterial cell, based on similarities between a bacterial cell and mitochondrial membranes. One strategy that is already developed is to tag the lysosome with a cancer cell-specific ligand for targeted delivery of the peptide [188]. Finally, designing AMPs as part of nanoparticles for delivery is another strategy that may improve PK properties of AMPs and should be explored [189–191]. All of these strategies for enhancing PK properties should be considered only when indicated, as AMPs are highly diverse in structure, which affects PK properties. [Figure: Strategy to improve the PK properties of AMPs adapted from Kelly et al., 2016 [183]The AMP P18 is amidated at the C-terminus. In addition, it is covalently bound to the protease cathepsin B-sensitive linker for the release of the cancer-active drug; this linker is also covalently attached to a polyethylene glycol (PEG) polymer, which is a hydrophilic moiety that serves as a protective shield from protease degradation and drug clearance.] The second criticism is based on an outdated notion of the highly impractical cost of peptide production. While cost remains a concern, peptide- and protein-based drugs have been used clinically for decades from anti-hypertensive (e.g. Lisinopril) [192–196] and anti-diabetic (e.g., insulin) [197, 198] to immune, antiviral (e.g., fuzeon), [199, 200] antibacterial, [201–203] and hormonal therapy [196]. Modern technology and larger scale synthesis have also significantly reduced the production cost of AMPs. The third concern is based on the fact that AMPs do not select their targets via specific receptors [204]. This nonreceptor-mediated recognition is one of the major reasons AMPs are less likely to invoke selection of resistance compared to current antibiotics/anticancer drugs and the basis for broad selectivity against diverse types of multidrug-resistant microbial pathogens and transformed cells. Lipid-mediated selectivity of AMPs should be considered as a major strength, not a weakness. These misconceptions against AMPs have considerably hampered the progress of their development, particularly AMP engineering for structural optimization in the United States. The success of the ACPs K6L9, LTX-315, and other engineered antibacterial AMPs [20, 167, 168, 175, 176] illustrates the need for AMP engineering and, thus, the establishment of a rational framework for predicting structural determinants of the selective killing of different target cells. Such a guideline for structural optimization, combined with PK-enhancing strategies, would enhance our ability to increase the therapeutic index of AMPs with significantly less trial and error. Despite the aforementioned challenges, there are a few AMPs being evaluated as anticancer (in addition to antimicrobial) agents in advanced phases of clinical development. The human cathelicidin LL37 is currently (2016) in Phase 2 clinical trial for melanoma (lesions at least 10 mm and not completely resectable) by intratumoral injections in patients with no known immune deficiency, a collaborative effort of M.D. Anderson Cancer Center and National Cancer Institute [205]. The first patients were enrolled in July 2015. LL37 is the single most studied human AMP [206–208]. It is normally found in human skin, reproductive, and respiratory systems and known to have multiple functional properties including (but not limited to) antibacterial, antiviral, antifungal, immunomodulatory, and anticancer activities [209–211]. Another AMP, LTX-315, is in phase 1 trial for PK and efficacy treatment of multiple types of transdermally accessible tumors. This is a lactoferrin-derived lytic peptide that binds and lyses tumor cells. The resulting tumor necrosis leads to enhanced presentation of tumor antigens and induced innate and adaptive immunity against the tumor as described above. This clinical trial started on October 28, 2013, and the last update (December 2016) indicates that LTX-315 is still in phase 1 “Open-label, multi-arm, multi-centre, multi-dose, dose Escalation Study” for exploration of efficacy as monotherapy or in combination with either ipilimumab or pembrolizumab in patients with transdermally accessible tumors” [212]. Noteworthy are other AMPs in clinical trial as anti-infective agents (e.g., OP-145 for otitis media and pexiganan for diabetic foot ulcer), but not as ACPs. Toward the goal for clinical applications, it is possible to improve the therapeutic index of current chemotherapeutic agents by considering combination therapy. Combining AMPs with a chemotherapeutic agent may help decrease dosage, which would result in lower toxicity. While the current clinical trial of LTX-315 including combination with immunotherapeutics (Ipilimumab or Pembrolizumab) is a step in the right direction, combination therapy using AMPs and chemotherapeutic agents needs to be explored for possible synergy [183]. Concluding remarks Since the discovery of AMPs more than three decades ago, no other class of compounds has matched their versatility as multifunctional compounds. AMPs have the potential to become the only class of drugs that can be used against polymicrobial co-infections (e.g., bacterial and viral [213]) and cancer. However, the multifunctionality determined by a typical AMP structure suggests that no single property is completely optimized in natural AMPs in the context of maintaining multiple functions. Rational peptide engineering is essential to AMP development for clinical applications. An important task is to dissect the structural determinants of each property to uncouple each of AMP functions for “application-specific optimization”. Only when such studies are conducted in a systematic way will we begin to significantly explore the clinical potential of AMPs as a diverse class of therapeutics. AMP research has been largely occurring outside of the United States. Despite a vast literature in AMP research, this is still an area that is critically underfunded by the National Institute of Health (NIH). Because of the initial failure of AMPs to reach the Clinique, the resulting bias has largely hindered the advancement of AMP research in the United States. Hence, there is a pressing need for the NIH and pharmaceutical companies to support more AMP research to collect the evidence necessary to assess whether the promise of AMPs will ever come to fruition. As an essential component of the immune system, AMPs warrant such exploration. ACKNOWLEDGMENTS AND FUNDING This research is supported by NIH awards R01 HL091938, HL-125128, and a grant (CIA-123062) from Flight Attendant Medical Research Institute. REFERENCES1HashimDBoffettaPLa VecchiaCRotaMBertuccioPMalvezziMNegriEThe global decrease in cancer mortality: trends and disparitiesAnn Oncol2016279269332680215710.1093/annonc/mdw0272TorreLASiegelRLWardEMJemalAGlobal Cancer Incidence and Mortality Rates and Trends–An UpdateCancer Epidemiol Biomarkers Prev20162516272666788610.1158/1055-9965.EPI-15-05783SaikaKMachiiRCancer mortality attributable to tobacco by region based on the WHO Global ReportJpn J Clin Oncol201242771722284413110.1093/jjco/hys1174ShibuyaKMathersCDBoschi-PintoCLopezADMurrayCJGlobal and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000BMC Cancer20022371250243210.1186/1471-2407-2-37PMC1493645DaskivichTJLife Expectancy and Treatment Choice for Men with High-risk Prostate CancerEur Urol20156859602581368910.1016/j.eururo.2015.01.0066ArringtonAKGoldsteinLKruperLVitoCYimJChenSLLife expectancy after curative-intent treatment of breast cancer: impact on long-term follow-up careAm Surg20148060409248878007DelpierreCLamySKelly-IrvingMMoliniéFVeltenMTretarreBWoronoffASBuemiALapôtre-LedouxBBaraSGuizardAVColonnaMGrosclaudePLife expectancy estimates as a key factor in over-treatment: the case of prostate cancerCancer Epidemiol201337462682362348910.1016/j.canep.2013.03.0148RepettoLComandiniDMammolitiSLife expectancy, comorbidity and quality of life: the treatment equation in the older cancer patientsCrit Rev Oncol Hematol200137147521116658810.1016/s1040-8428(00)00104-99HaybittleJLLife expectancy as a measurement of the benefit shown by clinical trials of treatment for early breast cancerClin Oncol (R Coll Radiol)1998109294961089710.1016/s0936-6555(05)80485-610KolbergHCVillena-HeinsenCDemlMMKraemerSDiedrichKFriedrichMRelationship between chemotherapy with paclitaxel, cisplatin, vinorelbine and titanocene dichloride and expression of proliferation markers and tumour suppressor gene p53 in human ovarian cancer xenografts in nude miceEur J Gynaecol Oncol2005263984021612218711PierardGEFocanCLapiereCMCell proliferation in a malignant angioendothelioma during sequential chemotherapyJ Cutan Pathol1979647948552153910.1111/j.1600-0560.1979.tb01174.x12KatoYSatoJKatoRTakataRObaraW[Side effect and supportive care to combination of gemcitabine and cisplatin chemotherapy for the advanced urothelial cancer]. [Article in Japanese]Nihon rinsho2015736096132583183213LarsenMERowntreeJYoungAMPearsonSSmithJGibsonOJWeaverATarassenkoLChemotherapy side-effect management using mobile phonesConf Proc IEEE Eng Med Biol Soc20082008515251551916387710.1109/IEMBS.2008.465037414SaxenaACancer chemotherapy and its side effect managementNurs J India200697109101705856115ChismDDDe SilvaDWhangYEMechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancerExpert Rev Anticancer Ther2014141369782492763110.1586/14737140.2014.928594PMC422135916ChatterjeeSDamleSGSharmaAKMechanisms of resistance against cancer therapeutic drugsCurr Pharm Biotechnol2014151105122542965110.2174/138920101566614112612395217TamburrinoAPiroGCarboneCTortoraGMelisiDMechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapyFront Pharmacol20134562364121610.3389/fphar.2013.00056PMC363940718DeslouchesBSteckbeckJDCraigoJKDoiYBurnsJLMontelaroRCEngineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogensAntimicrob Agents Chemother2015591329332542147310.1128/AAC.03937-14PMC433588319SteckbeckJDDeslouchesBMontelaroRCAntimicrobial peptides: new drugs for bad bugs?Expert Opin Biol Ther20141411142420606210.1517/14712598.2013.844227PMC410970520DeslouchesBSteckbeckJDCraigoJKDoiYMietznerTAMontelaroRCRational design of engineered cationic antimicrobial peptides consisting exclusively of arginine and tryptophan, and their activity against multidrug-resistant pathogensAntimicrob Agents Chemother2013572511212350727810.1128/AAC.02218-12PMC371617121DuttaPDasSMammalian Antimicrobial Peptides: Promising Therapeutic Targets Against Infection and Chronic InflammationCurr Top Med Chem201616991292613911110.2174/156802661566615070312181922HiemstraPSAmatngalimGDvan der DoesAMTaubeCAntimicrobial Peptides and Innate Lung Defenses: Role in Infectious and Noninfectious Lung Diseases and Therapeutic ApplicationsChest2016149545512650203510.1378/chest.15-135323ShagaghiNPalomboEAClaytonAHBhaveMArchetypal tryptophan-rich antimicrobial peptides: properties and applicationsWorld J Microbiol Biotechnol201632312674880810.1007/s11274-015-1986-z24SchmittPRosaRDDestoumieux-GarzonDAn intimate link between antimicrobial peptide sequence diversity and binding to essential components of bacterial membranesBiochim Biophys Acta201618589589702649839710.1016/j.bbamem.2015.10.01125Aguilera-MendozaLMarrero-PonceYTellez-IbarraRLlorente-QuesadaMTSalgadoJBarigyeSJLiuJOverlap and diversity in antimicrobial peptide databases: compiling a non-redundant set of sequencesBioinformatics2015312553592581967310.1093/bioinformatics/btv18026HeXYangSWeiLLiuRLaiRRongMAntimicrobial peptide diversity in the skin of the torrent frog, Amolops jingdongensisAmino Acids2013444814872282880910.1007/s00726-012-1358-z27PadhiAVergheseBMolecular diversity and evolution of myticin-C antimicrobial peptide variants in the Mediterranean mussel, Mytilus galloprovincialisPeptides20082910941011844067010.1016/j.peptides.2008.03.00728DennisonSRWallaceJHarrisFPhoenixDAAmphiphilic alpha-helical antimicrobial peptides and their structure/function relationshipsProtein Pept Lett20051231391563880110.2174/092986605340608429BuletPHetruCDimarcqJLHoffmannDAntimicrobial peptides in insects; structure and functionDev Comp Immunol199923329441042642610.1016/s0145-305x(99)00015-430HwangPMVogelHJStructure-function relationships of antimicrobial peptidesBiochem Cell Biol199876235246992369210.1139/bcb-76-2-3-23531SitaramNNagarajRHost-defense antimicrobial peptides: importance of structure for activityCurr Pharm Des20028727421194516810.2174/138161202339535832Guzmán-RodríguezJJOchoa-ZarzosaALopez-GomezRLopez-MezaJEPlant antimicrobial peptides as potential anticancer agentsBiomed Res Int201520157350872581533310.1155/2015/735087PMC435985233FarkasAMarótiGKeresztAKondorosiÉComparative Analysis of the Bacterial Membrane Disruption Effect of Two Natural Plant Antimicrobial PeptidesFront Microbiol20178512816793810.3389/fmicb.2017.00051PMC525336834GomarascaMC Martins TFGreuneLHardwidgePRSchmidtMARüterCBacterial-derived cell-penetrating peptides deliver gentamicin to kill intracellular pathogensAntimicrob Agents Chemother201761e02545162809615610.1128/AAC.02545-16PMC536571335CoelhoMLde Souza DuarteAFdo Carmo de Freire BastosM.Bacterial Labionin-Containing Peptides and Sactibiotics: Unusual Types of Antimicrobial Peptides with Potential Use in Clinical Settings (A Review)Curr Top Med Chem2016171177119810.2174/15680266166661609301448092769704536JungHJKimYLeeHBKwonHJAntiangiogenic activity of the lipophilic antimicrobial peptides from an endophytic bacterial strain isolated from red pepper leafMol Cells201538273782555637010.14348/molcells.2015.2320PMC436372837GomesKMDuarteRSde Freire BastosMDLantibiotics produced by Actinobacteria and their potential applications (a review)Microbiology2017163109212827026210.1099/mic.0.00039738BarbosaAAMantovaniHCJainSBacteriocins from lactic acid bacteria and their potential in the preservation of fruit productsCrit Rev Biotechnol2017311310.1080/07388551.2016.12623232804935039AhmadVKhanMSJamalQMAlzohairyMAAl KaraawiMASiddiquiMUAntimicrobial potential of bacteriocins: in therapy, agriculture and food preservationInt J Antimicrob Agents2017491112777349710.1016/j.ijantimicag.2016.08.01640PirtskhalavaMGabrielianACruzPGriggsHLSquiresRBHurtDEGrigolavaMChubinidzeMGogoladzeGVishnepolskyBAlekseyevVRosenthalATartakovskyMDBAASP v.2: an enhanced database of structure and antimicrobial/cytotoxic activity of natural and synthetic peptidesNucleic Acids Res20164465032706014210.1093/nar/gkw243PMC499486241WaghuFHBaraiRSGurungPIdicula-ThomasSCAMPR3: a database on sequences, structures and signatures of antimicrobial peptidesNucleic Acids Res201644D1094972646747510.1093/nar/gkv1051PMC470278742LiuYEichlerJPischetsriederMVirtual screening of a milk peptide database for the identification of food-derived antimicrobial peptidesMol Nutr Food Res201559224322542620258610.1002/mnfr.20150018243Di LucaMMaccariGMaisettaGBatoniGBaAMPs: the database of biofilm-active antimicrobial peptidesBiofouling201531193992576040410.1080/08927014.2015.102134044NiarchouAAlexandridouAAthanasiadisESpyrouGC-PAmP: large scale analysis and database construction containing high scoring computationally predicted antimicrobial peptides for all the available plant speciesPLoS One20138e797282424455010.1371/journal.pone.0079728PMC382356345ZhaoXWuHLuHLiGHuangQLAMP: A Database Linking Antimicrobial PeptidesPLoS One20138e665572382554310.1371/journal.pone.0066557PMC368895746PiottoSPSessaLConcilioSIannelliPYADAMP: yet another database of antimicrobial peptidesInt J Antimicrob Agents201239346512232512310.1016/j.ijantimicag.2011.12.00347LiYChenZRAPD: a database of recombinantly-produced antimicrobial peptidesFEMS Microbiol Lett2008289126291905410210.1111/j.1574-6968.2008.01357.x48FjellCDHancockRECherkasovAAMPer: a database and an automated discovery tool for antimicrobial peptidesBioinformatics2007231148551734149710.1093/bioinformatics/btm06849HancockRESahlHGAntimicrobial and host-defense peptides as new anti-infective therapeutic strategiesNat Biotechnol2006241551571716006110.1038/nbt126750HilpertKElliottMRVolkmer-EngertRHenkleinPDoniniOZhouQWinklerDFHancockRESequence requirements and an optimization strategy for short antimicrobial peptidesChem Biol2006131101071705261410.1016/j.chembiol.2006.08.01451HancockREBrownKLMookherjeeNHost defence peptides from invertebrates—emerging antimicrobial strategiesImmunobiology2006211315221669792210.1016/j.imbio.2005.10.01752BrownKLHancockRECationic host defense (antimicrobial) peptidesCurr Opin Immunol20061824301633736510.1016/j.coi.2005.11.00453SobloskyLRamamoorthyAChenZMembrane interaction of antimicrobial peptides using E. coli lipid extract as model bacterial cell membranes and SFG spectroscopyChem Phys Lipids201518720332570731210.1016/j.chemphyslip.2015.02.003PMC438550054KamimoriHBlazykJAguilarMILipid membrane-binding properties of tryptophan analogues of linear amphipathic beta-sheet cationic antimicrobial peptides using surface plasmon resonanceBiol Pharm Bull200528148501563518010.1248/bpb.28.14855Maget-DanaRThe monolayer technique: a potent tool for studying the interfacial properties of antimicrobial and membrane-lytic peptides and their interactions with lipid membranesBiochim Biophys Acta19991462109401059030510.1016/s0005-2736(99)00203-556WangCChenTZhangNYangMLiBLüXCaoXLingCMelittin, a major component of bee venom, sensitizes human hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating CaMKII-TAK1-JNK/p38 and inhibiting IkappaBalpha kinase-NFkappaBJ Biol Chem20092843804131907443610.1074/jbc.M80719120057MangoniMLPapoNSaugarJMBarraDShaiYSimmacoMRivasLEffect of natural L- to D-amino acid conversion on the organization, membrane binding, and biological function of the antimicrobial peptides bombinins HBiochemistry2006454266761656660110.1021/bi052150y58PapoNSegerDMakovitzkiAKalchenkoVEshharZDeganiHShaiYInhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptideCancer Res2006665371781670746410.1158/0008-5472.CAN-05-456959WakabayashiHMatsumotoHHashimotoKTeraguchiSTakaseMHayasawaHN-Acylated and D enantiomer derivatives of a nonamer core peptide of lactoferricin B showing improved antimicrobial activityAntimicrob Agents Chemother1999431267691022394910.1128/aac.43.5.1267PMC8925660ShangDZhangQDongWLiangHBiXThe effects of LPS on the activity of Trp-containing antimicrobial peptides against Gram-negative bacteria and endotoxin neutralizationActa Biomater201633153652680420510.1016/j.actbio.2016.01.01961NanYHBangJKJacobBParkISShinSYProkaryotic selectivity and LPS-neutralizing activity of short antimicrobial peptides designed from the human antimicrobial peptide LL-37Peptides201235239472252119610.1016/j.peptides.2012.04.00462GustafssonAOlinAILjunggrenLLPS interactions with immobilized and soluble antimicrobial peptidesScand J Clin Lab Invest2010701942002023303810.3109/0036551100366362263GiulianiAPirriGRinaldiACAntimicrobial peptides: the LPS connectionMethods Mol Biol20106181371542009486310.1007/978-1-60761-594-1_1064MalanovicNLeberRSchmuckMKriechbaumMCordfunkeRADrijfhoutJWde BreijANibberingPHKolbDLohnerKPhospholipid-driven differences determine the action of the synthetic antimicrobial peptide OP-145 on Gram-positive bacterial and mammalian membrane model systemsBiochim Biophys Acta20151848243724472621029910.1016/j.bbamem.2015.07.01065JasirAKasprzykowskiFLindströmVSchalénCGrubbANew antimicrobial peptide active against Gram-positive pathogensIndian J Med Res200411974761523216666JasirAKasprzykowskiFKasprzykowskaRLindstromVSchalenCGrubbANew antimicrobial cystatin C-based peptide active against gram-positive bacterial pathogens, including methicillin-resistant Staphylococcus aureus and multiresistant coagulase-negative staphylococciAPMIS2003111100410101462926610.1111/j.1600-0463.2003.t01-1-apm1111110.x67RuanYShenTWangYHouMLiJSunTAntimicrobial peptide LL-37 attenuates LTA induced inflammatory effect in macrophagesInt Immunopharmacol201315575802337593410.1016/j.intimp.2013.01.01268GustafssonASigelSLjunggrenLThe antimicrobial peptide LL37 and its truncated derivatives potentiates proinflammatory cytokine induction by lipoteichoic acid in whole bloodScand J Clin Lab Invest2010705125182087396810.3109/00365513.2010.52125569NgTBCheungRCWongJHYeXJAntimicrobial activity of defensins and defensin-like peptides with special emphasis on those from fungi and invertebrate animalsCurr Protein Pept Sci2013145155312396834910.2174/1389203711314999006870CrackLRJonesLMalavigeGNPatelVOggGSHuman antimicrobial peptides LL-37 and human beta-defensin-2 reduce viral replication in keratinocytes infected with varicella zoster virusClin Exp Dermatol2012375345432263991910.1111/j.1365-2230.2012.04305.x71NavaGMEscorciaMCastanedaMPMolecular diversity of the antimicrobial domain of beta-defensin 3 and homologous peptidesComp Funct Genomics20099836361988843910.1155/2009/983636PMC277132872NanYHBangJKShinSYDesign of novel indolicidin-derived antimicrobial peptides with enhanced cell specificity and potent anti-inflammatory activityPeptides200930832381942875810.1016/j.peptides.2009.01.01573LadokhinASSelstedMEWhiteSHCD spectra of indolicidin antimicrobial peptides suggest turns, not polyproline helixBiochemistry19993812313191049379910.1021/bi990793674HollmannAMartínezMNogueraMEAugustoMTDisalvoASantosNCSemorileLMaffíaPCRole of amphipathicity and hydrophobicity in the balance between hemolysis and peptide-membrane interactions of three related antimicrobial peptidesColloids Surf B Biointerfaces2016141528362689666010.1016/j.colsurfb.2016.02.00375SonMLeeYHwangHHyunSYuJDisruption of interactions between hydrophobic residues on nonpolar faces is a key determinant in decreasing hemolysis and increasing antimicrobial activities of α-helical amphipathic peptidesChemMedChem201381638422389407910.1002/cmdc.20130026476UtsugiTSchroitAJConnorJBucanaCDFidlerIJElevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytesCancer Res199151306266203224777GerberDEHaoGWatkinsLStaffordJHAndersonJHolbeinBOzOKMathewsDThorpePEHassanGKumarABrekkenRASunXTumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenograftsAm J Nucl Med Mol Imaging2015549350326550540PMC462017678KenisHReutelingspergerCTargeting phosphatidylserine in anti-cancer therapyCurr Pharm Des2009152719231968934210.2174/13816120978892390379BeversEMWilliamsonPLGetting to the Outer Leaflet: Physiology of Phosphatidylserine Exposure at the Plasma MembranePhysiol Rev201696605452693686710.1152/physrev.00020.201580ConnorJPakCCSchroitAJExposure of phosphatidylserine in the outer leaflet of human red blood cells. Relationship to cell density, cell age, and clearance by mononuclear cellsJ Biol Chem19942692399404830056581KoopmanGReutelingspergerCPKuijtenGAKeehnenRMPalsSTvan OersMHAnnexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosisBlood199484141520806893882MartinSJReutelingspergerCPMcGahonAJRaderJAvan SchieRCLaFaceDMGreenDREarly redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and AblJ Exp Med199518215451556759522410.1084/jem.182.5.1545PMC219218283LeeSHMengXWFlattenKSLoegeringDAKaufmannSHPhosphatidylserine exposure during apoptosis reflects bidirectional trafficking between plasma membrane and cytoplasmCell Death Differ20132064762285854410.1038/cdd.2012.93PMC352463984ColeCLRushtonGJaysonGCAvizienyteEOvarian cancer cell heparan sulfate 6-O-sulfotransferases regulate an angiogenic program induced by heparin-binding epidermal growth factor (EGF)-like growth factor/EGF receptor signalingJ Biol Chem201428910488105012456348310.1074/jbc.M113.534263PMC403617085KontroHJoenvääräSHaglundCRenkonenRComparison of sialylated N-glycopeptide levels in serum of pancreatic cancer patients, acute pancreatitis patients, and healthy controlsProteomics2014141713232484199810.1002/pmic.20130027086TianYEstevaFJSongJZhangHAltered expression of sialylated glycoproteins in breast cancer using hydrazide chemistry and mass spectrometryMol Cell Proteomics201211M111 01140310.1074/mcp.M111.011403PMC34338932231836987LeeCSTaibNAAshrafzadehAFadzliFHarunFRahmatKHoongSMAbdul-RahmanPSHashimOHUnmasking Heavily O-Glycosylated Serum Proteins Using Perchloric Acid: Identification of Serum Proteoglycan 4 and Protease C1 Inhibitor as Molecular Indicators for Screening of Breast CancerPLoS One201611e01495512689088110.1371/journal.pone.0149551PMC475873388MuAKLimBKHashimOHShuibASIdentification of O-glycosylated proteins that are aberrantly excreted in the urine of patients with early stage ovarian cancerInt J Mol Sci201314792379312357995510.3390/ijms14047923PMC364572489OsinagaEExpression of cancer-associated simple mucin-type O-glycosylated antigens in parasitesIUBMB Life200759269731750596410.1080/1521654060118855390YoonWHParkHDLimKHwangBDEffect of O-glycosylated mucin on invasion and metastasis of HM7 human colon cancer cellsBiochem Biophys Res Commun199622269499865190710.1006/bbrc.1996.080691FadnesBRekdalOUhlin-HansenLThe anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cellsBMC Cancer200991831952749010.1186/1471-2407-9-183PMC270365092SokMSentjurcMScharaMStareJRottTCell membrane fluidity and prognosis of lung cancerAnn Thorac Surg200273156715711202255110.1016/s0003-4975(02)03458-693SokMSentjurcMScharaMMembrane fluidity characteristics of human lung cancerCancer Lett1999139215201039518110.1016/s0304-3835(99)00044-094BergerMMottaCBoiretNAublet-CuvelierBBonhommeJTravadePMembrane fluidity and adherence to extracellular matrix components are related to blast cell count in acute myeloid leukemiaLeukem & lymphom19941529730210.3109/10428199409049727786627895LiXShenBChenQZhangXYeYWangFZhangXAntitumor effects of cecropin B-LHRH’ on drug-resistant ovarian and endometrial cancer cellsBMC Cancer2016162512702190310.1186/s12885-016-2287-0PMC480903696SuttmannHRetzMPaulsenFHarderJZwergelUKamradtJWullichBUntereggerGStockleMLehmannJAntimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cellsBMC Urol2008851831588110.1186/1471-2490-8-5PMC227651197HuiLLeungKChenHMThe combined effects of antibacterial peptide cecropin A and anti-cancer agents on leukemia cellsAnticancer Res2002222811161253000198LiuYChenLGongZShenLKaoCHockJMSunLLiXLovastatin enhances adenovirus-mediated TRAIL induced apoptosis by depleting cholesterol of lipid rafts and affecting CAR and death receptor expression of prostate cancer cellsOncotarget2015630557010.18632/oncotarget.307325605010PMC441363799ZhuangLLinJLuMLSolomonKRFreemanMRCholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cellsCancer Res20026222273111956073100MulderKCLimaLAMirandaVJDiasSCFrancoOLCurrent scenario of peptide-based drugs: the key roles of cationic antitumor and antiviral peptidesFront Microbiol201343212419881410.3389/fmicb.2013.00321PMC3813893101RothanHAMohamedZSuhaebAMRahmanNAYusofRAntiviral cationic peptides as a strategy for innovation in global health therapeutics for dengue virus: high yield production of the biologically active recombinant plectasin peptideOmics2013175605672404436610.1089/omi.2013.0056PMC3814901102ChanSCHuiLChenHMEnhancement of the cytolytic effect of anti-bacterial cecropin by the microvilli of cancer cellsAnticancer Res1998184467749891511103KolataGBMicrovilli: a major difference between normal and cancer cells?Science1975188819201776988510.1126/science.188.4190.819104LacerdaAFVasconcelosEAPelegriniPBGrossi de SaMFAntifungal defensins and their role in plant defenseFront Microbiol201451162476508610.3389/fmicb.2014.00116PMC3980092105VriensKCammueBPThevissenKAntifungal plant defensins: mechanisms of action and productionMolecules201419122803032515385710.3390/molecules190812280PMC6271847106LehrerRIBartonADaherKAHarwigSSGanzTSelstedMEInteraction of human defensins with Escherichia coli. Mechanism of bactericidal activityJ Clin Invest19898455361266833410.1172/JCI114198PMC548915107PanyutichAVVoitenokNNLehrerRIGanzTAn enzyme immunoassay for human defensinsJ Immunol Methods199114114955188042210.1016/0022-1759(91)90141-2108VenkataramanNColeALRuchalaPWaringAJLehrerRIStuchlikOPohlJColeAMReawakening retrocyclins: ancestral human defensins active against HIV-1PLoS Biol20097e951940275210.1371/journal.pbio.1000095PMC2672613109MuñozAChuMMarrisPISagaramUSKaurJShahDMReadNDSpecific domains of plant defensins differentially disrupt colony initiation, cell fusion and calcium homeostasis in Neurospora crassaMol Microbiol2014921357742477306010.1111/mmi.12634110XuNWangYSPanWBXiaoBWenYJChenXCChenLJDengHXYouJKanBFuAFLiDZhaoXWeiYQHuman alpha-defensin-1 inhibits growth of human lung adenocarcinoma xenograft in nude miceMol Cancer Ther200871588971856622910.1158/1535-7163.MCT-08-0010111RenXYLiWYXuM[Expression of human beta-defensin-2 in laryngeal squamous cell carcinoma and its correlation with CD1a(+) dendritic cells infiltrating in tumor.]. [Article in Chinese]Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi20094410293320193620112GanzTOrenALehrerRIDefensins: microbicidal and cytotoxic peptides of mammalian host defense cellsMed Microbiol Immunol (Berl)199218199105140646110.1007/BF00189428113KaganBLGanzTLehrerRIDefensins: a family of antimicrobial and cytotoxic peptidesToxicology19948713149751275810.1016/0300-483x(94)90158-9114LehrerRILichtensteinAKGanzTDefensins: antimicrobial and cytotoxic peptides of mammalian cellsAnnu Rev Immunol19931110528847655810.1146/annurev.iy.11.040193.000541115LichtensteinAKGanzTNguyenTMSelstedMELehrerRIMechanism of target cytolysis by peptide defensins. Target cell metabolic activities, possibly involving endocytosis, are crucial for expression of cytotoxicityJ Immunol19881402686943162745116CrucianiRABarkerJLZasloffMChenHCColamoniciOAntibiotic magainins exert cytolytic activity against transformed cell lines through channel formationProc Natl Acad Sci USA199188379296170888710.1073/pnas.88.9.3792PMC51539117MooreKSBevinsCLBrasseurMMTomassiniNTurnerKEckHZasloffMAntimicrobial peptides in the stomach of Xenopus laevisJ Biol Chem199126619851571717472118SoraviaEMartiniGZasloffMAntimicrobial properties of peptides from Xenopus granular gland secretionsFEBS Lett198822833740312506610.1016/0014-5793(88)80027-9119ZasloffMMagainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursorProc Natl Acad Sci USA198784544953329938410.1073/pnas.84.15.5449PMC298875120WesterhoffHVHendlerRWZasloffMJuretićDInteractions between a new class of eukaryotic antimicrobial agents and isolated rat liver mitochondriaBiochim Biophys Acta198997536169275804210.1016/s0005-2728(89)80344-5121MerrifieldRBVizioliLDBomanHGSynthesis of the antibacterial peptide cecropin A (1–33)Biochemistry198221502031681448210.1021/bi00263a028122HultmarkDEngstromABennichHKapurRBomanHGInsect immunity: isolation and structure of cecropin D and four minor antibacterial components from Cecropia pupaeEur J Biochem1982127207217714075510.1111/j.1432-1033.1982.tb06857.x123ShinSYKangJHJangSYKimYKimKLHahmKSEffects of the hinge region of cecropin A(1–8)-magainin 2(1–12), a synthetic antimicrobial peptide, on liposomes, bacterial and tumor cellsBiochim Biophys Acta20001463209181067550010.1016/s0005-2736(99)00210-2124HsuJCLinLCTzenJTChenJYCharacteristics of the antitumor activities in tumor cells and modulation of the inflammatory response in RAW264.7 cells of a novel antimicrobial peptide, chrysophsin-1, from the red sea bream (Chrysophrys major)Peptides201132900102134930810.1016/j.peptides.2011.02.013125CirioniOSimonettiOPierpaoliEBaruccaAGhiselliROrlandoFPelloniMMinardiDTrombettoniMMGuerrieriMOffidaniAGiacomettiAProvincialiMEnhanced Efficacy of Combinations of Pexiganan with Colistin Versus Acinetobacter Baumannii in Experimental SepsisShock201646219252684963010.1097/SHK.0000000000000584126ZhangXLJiangAMMaZYLiXBXiongYYDouJFWangJFThe synthetic antimicrobial peptide pexiganan and its nanoparticles (PNPs) exhibit the anti-helicobacter pylori activity in vitro and in vivoMolecules2015203972852573853910.3390/molecules20033972PMC6272436127Dipexium Pharmaceuticals IDipexium Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial Of Locilex® In Patients With Mild Infections Of Diabetic Foot Ulcershttp://contentequisolvenet/dipexiumpharmaceuticals/news/2014–07-17_Dipexium_Pharmaceuticals_Initiates_Pivotal_Phase_54pdf, PRNewswire2014128LiuSYangHWanLCaiHWLiSFLiYPChengJQLuXFEnhancement of cytotoxicity of antimicrobial peptide magainin II in tumor cells by bombesin-targeted deliveryActa Pharmacol Sin20113279882113199810.1038/aps.2010.162PMC4003308129DominguesTMRiskeKAMirandaARevealing the lytic mechanism of the antimicrobial peptide gomesin by observing giant unilamellar vesiclesLangmuir20102611077110842035604010.1021/la100662a130RodriguesEGDobroffASCavarsanCFPaschoalinTNimrichterLMortaraRASantosELFázioMAMirandaADaffreSTravassosLREffective topical treatment of subcutaneous murine B16F10-Nex2 melanoma by the antimicrobial peptide gomesinNeoplasia20081061681823163910.1593/neo.07885PMC2213900131TomasinsigLSkerlavajBPapoNGiabbaiBShaiYZanettiMMechanistic and functional studies of the interaction of a proline-rich antimicrobial peptide with mammalian cellsJ Biol Chem2006281383911625796910.1074/jbc.M510354200132PapoNBraunsteinAEshharZShaiYSuppression of human prostate tumor growth in mice by a cytolytic D-, L-amino Acid Peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretionCancer Res2004645779861531392010.1158/0008-5472.CAN-04-1438133BraunsteinAPapoNShaiYIn vitro activity and potency of an intravenously injected antimicrobial peptide and its DL amino acid analog in mice infected with bacteriaAntimicrob Agents Chemother2004483127291527313110.1128/AAC.48.8.3127-3129.2004PMC478488134CichońTSmolarczykRMatuszczakSBarczykMJaroszMSzalaSD-K6L 9 peptide combination with IL-12 inhibits the recurrence of tumors in miceArch Immunol Ther Exp (Warsz)201462341512448772210.1007/s00005-014-0268-zPMC4092230135JingWSvendsenJSVogelHJComparison of NMR structures and model-membrane interactions of 15-residue antimicrobial peptides derived from bovine lactoferricinBiochem Cell Biol200684312261693680210.1139/o06-052136UmeyamaMKiraANishimuraKNaitoAInteractions of bovine lactoferricin with acidic phospholipid bilayers and its antimicrobial activity as studied by solid-state NMRBiochim Biophys Acta20061758152315281688468310.1016/j.bbamem.2006.06.014137LonghiCConteMPRanaldiSPentaMValentiPTinariASupertiFSegantiLApoptotic death of Listeria monocytogenes-infected human macrophages induced by lactoferricin B, a bovine lactoferrin-derived peptideInt J Immunopathol Pharmacol2005183173251588825410.1177/039463200501800214138TomitaMWakabayashiHYamauchiKTeraguchiSHayasawaHBovine lactoferrin and lactoferricin derived from milk: production and applicationsBiochem Cell Biol200280109121190863310.1139/o01-230139YooYCWatanabeSWatanabeRHataKShimazakiKAzumaIBovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in miceJpn J Cancer Res19978818490911974710.1111/j.1349-7006.1997.tb00364.xPMC5921353140HaugBESvendsenJSThe role of tryptophan in the antibacterial activity of a 15-residue bovine lactoferricin peptideJ Pept Sci200171901961135446210.1002/psc.318141TanakaTOmataYSaitoAShimazakiKYamauchiKTakaseMKawaseKIgarashiKSuzukiNToxoplasma gondii: parasiticidal effects of bovine lactoferricin against parasitesExp Parasitol199581614617854300510.1006/expr.1995.1157142BellamyWWakabayashiHTakaseMKawaseKShimamuraSTomitaMKilling of Candida albicans by lactoferricin B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrinMed Microbiol Immunol (Berl)199318297105833210510.1007/BF00189377143BellamyWTakaseMWakabayashiHKawaseKTomitaMAntibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrinJ Appl Bacteriol19927347279149090810.1111/j.1365-2672.1992.tb05007.x144YooYCWatanabeSWatanabeRHataKShimazakiKAzumaIBovine lactoferrin and Lactoferricin inhibit tumor metastasis in miceAdv Exp Med Biol199844328591978137110.1007/978-1-4757-9068-9_35145YooYCWatanabeRKoikeYMitobeMShimazakiKWatanabeSAzumaIApoptosis in human leukemic cells induced by lactoferricin, a bovine milk protein-derived peptide: involvement of reactive oxygen speciesBiochem Biophys Res Commun199723762428929941510.1006/bbrc.1997.7199146EliassenLTBergeGSveinbjørnssonBSvendsenJSVorlandLHRekdalØEvidence for a direct antitumor mechanism of action of bovine lactoferricinAnticancer Res20022227031012529985147EliassenLTHaugBEBergeGRekdalOEnhanced antitumour activity of 15-residue bovine lactoferricin derivatives containing bulky aromatic amino acids and lipophilic N-terminal modificationsJ Pept Sci200395105171295239210.1002/psc.472148HaugBECamilioKAEliassenLTStensenWSvendsenJSBergKMortensenBSerinGMirjoletJFBichatFRekdalØDiscovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic PeptideJ Med Chem2016592918272698262310.1021/acs.jmedchem.5b02025149YamazakiTPittJMVetizouMMarabelleAFloresCRekdalOKroemerGZitvogelLThe oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockadeCell Death Differ201623100410152708245310.1038/cdd.2016.35PMC4987735150SistiguAManicGVitaleILTX-315, CAPtivating immunity with necrosisCell Cycle201615117611772698668910.1080/15384101.2016.1160609PMC4889301151ZhouHForveilleSSauvatAYamazakiTSenovillaLMaYLiuPYangHBezuLMüllerKZitvogelLRekdalØKeppOKroemerGThe oncolytic peptide LTX-315 triggers immunogenic cell deathCell Death Dis20167e21342696268410.1038/cddis.2016.47PMC4823948152ForveilleSZhouHSauvatABezuLMullerKLiuPZitvogelLPierronGRekdalOKeppOKroemerGThe oncolytic peptide LTX-315 triggers necrotic cell deathCell Cycle201514350635122656686910.1080/15384101.2015.1093710PMC4825625153EikeLMYangNRekdalØSveinbjørnssonBThe oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cellsOncotarget20156349102310.18632/oncotarget.530826472184PMC4741498154ZhouHForveilleSSauvatASicaVIzzoVDurandSMüllerKLiuPZitvogelLRekdalØKeppOKroemerGThe oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilizationOncotarget201562659961410.18632/oncotarget.561326378049PMC4694939155CamilioKARekdalOSveinbjörnssonBLTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agentOncoImmunology20143e291812508333310.4161/onci.29181PMC4108458156CamilioKABergeGRavuriCSRekdalOSveinbjørnssonBComplete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315Cancer Immunol Immunother201463601132467690110.1007/s00262-014-1540-0PMC4024132157FrankMGWeberMDWatkinsLRMaierSFStress sounds the alarmin: The role of the danger-associated molecular pattern HMGB1 in stress-induced neuroinflammatory primingBrain Behav Immun201548172581680010.1016/j.bbi.2015.03.010PMC4508196158TheansungnoenTMaijaroenSJangprommaNYaraksaNDaduangSTemsiripongTDaduangJKlaynongsruangSCationic Antimicrobial Peptides Derived from Crocodylus siamensis Leukocyte Extract, Revealing Anticancer Activity and Apoptotic Induction on Human Cervical Cancer CellsProtein J201635202112712946210.1007/s10930-016-9662-1159RissoABraidotESordanoMCVianelloAMacrìFSkerlavajBZanettiMGennaroRBernardiPBMAP-28, an antibiotic peptide of innate immunity, induces cell death through opening of the mitochondrial permeability transition poreMol Cell Biol2002221926351186506910.1128/MCB.22.6.1926-1935.2002PMC135593160LeeHSParkCBKimJMJangSAParkIYKimMSChoJHKimSCMechanism of anticancer activity of buforin IIb, a histone H2A-derived peptideCancer Lett200827147551861732310.1016/j.canlet.2008.05.041161MaiJCMiZKimSHNgBRobbinsPDA proapoptotic peptide for the treatment of solid tumorsCancer Res2001617709771211691780162HanYCuiZLiYHHsuWHLeeBHIn Vitroand in Vivo Anticancer Activity of Pardaxin against Proliferation and Growth of Oral Squamous Cell CarcinomaMar Drugs20151422670363110.3390/md14010002PMC4728499163TianWLiBZhangXDangWWangXTangHWangLCaoHChenTSuppression of tumor invasion and migration in breast cancer cells following delivery of siRNA against Stat3 with the antimicrobial peptide PR39Oncol Rep2012281362682279778210.3892/or.2012.1911164WuJParungoCWuGKangPMLahamRJSellkeFWSimonsMLiJPR39 inhibits apoptosis in hypoxic endothelial cells: role of inhibitor apoptosis protein-2Circulation20041091660671502388810.1161/01.CIR.0000124067.35915.E0165LiJPostMVolkRGaoYLiMMetaisCSatoKTsaiJAirdWRosenbergRDHamptonTGSellkeFCarmelietPSimonsMPR39, a peptide regulator of angiogenesisNat Med2000649551061382310.1038/71527166GhavamiSAsoodehAKlonischTHalaykoAJKadkhodaKKroczakTJGibsonSBBooyEPNaderi-ManeshHLosMBrevinin-2R(1) semi-selectively kills cancer cells by a distinct mechanism, which involves the lysosomal-mitochondrial death pathwayJ Cell Mol Med2008121005221849494110.1111/j.1582-4934.2008.00129.xPMC4401144167DeslouchesBGonzalezIADeAlmeidaDIslamKSteeleCMontelaroRCMietznerTADe novo-derived cationic antimicrobial peptide activity in a murine model of Pseudomonas aeruginosa bacteraemiaJ Antimicrob Chemother200760669721762369610.1093/jac/dkm253PMC3584960168DeslouchesBIslamKCraigoJKParanjapeSMMontelaroRCMietznerTAActivity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applicationsAntimicrob Agents Chemother2005493208161604892710.1128/AAC.49.8.3208-3216.2005PMC1196285169MakobongoMOGanczHCarpenterBMMcDanielDPMerrellDSThe oligo-acyl lysyl antimicrobial peptide C12K-2β12 exhibits a dual mechanism of action and demonstrates strong in vivo efficacy against Helicobacter pyloriAntimicrob Agents Chemother201256378902206454110.1128/AAC.00689-11PMC3256018170AranhaCGuptaSReddyKVContraceptive efficacy of antimicrobial peptide Nisin: in vitro and in vivo studiesContraception200469333381503341010.1016/j.contraception.2003.11.002171DesboisAPGemmellCGCootePJIn vivoefficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infectionsInt J Antimicrob Agents201035559652020648010.1016/j.ijantimicag.2010.01.016172NarayanaJLHuangHNWuCJChenJYEfficacy of the antimicrobial peptide TP4 against Helicobacter pylori infection: in vitro membrane perturbation via micellization and in vivo suppression of host immune responses in a mouse modelOncotarget20156129365410.18632/oncotarget.410126002554PMC4536990173ChanLYZhangVMHuangYHWatersNCBansalPSCraikDJDalyNLCyclization of the antimicrobial peptide gomesin with native chemical ligation: influences on stability and bioactivityChemBioChem201314617242342687710.1002/cbic.201300034174DennisonSRMortonLHPhoenixDAEffect of amidation on the antimicrobial peptide aurein 2.5 from Australian southern bell frogsProtein Pept Lett2012195865912251952910.2174/092986612800494110175DeslouchesBHasekMLCraigoJKSteckbeckJDMontelaroRCComparative functional properties of engineered cationic antimicrobial peptides consisting exclusively of tryptophan and either lysine or arginineJ Med Microbiol201665554652704619210.1099/jmm.0.000258PMC5042116176DeslouchesBPhadkeSMLazarevicVCascioMIslamKMontelaroRCMietznerTADe novo generation of cationic antimicrobial peptides: influence of length and tryptophan substitution on antimicrobial activityAntimicrob Agents Chemother200549316221561631110.1128/AAC.49.1.316-322.2005PMC538858177MorrisCJBeckKFoxMAUlaetoDClarkGCGumbletonMPegylation of antimicrobial peptides maintains the active peptide conformation, model membrane interactions, and antimicrobial activity while improving lung tissue biocompatibility following airway deliveryAntimicrob Agents Chemother20125632983082243097810.1128/AAC.06335-11PMC3370748178AndréMBesseSChezalJMMounetouEPEGylation enhances the tumor selectivity of melanoma-targeted conjugatesOrg Biomol Chem201513388972536328810.1039/c4ob01751j179Da PieveCBlackshawEMissailidisSPerkinsACPEGylation and biodistribution of an anti-MUC1 aptamer in MCF-7 tumor-bearing miceBioconjug Chem2012231377812270850010.1021/bc300128r180VineKLLobovSIndira ChandranVHarrisNLRansonMImproved pharmacokinetic and biodistribution properties of the selective urokinase inhibitor PAI-2 (SerpinB2) by site-specific PEGylation: implications for drug deliveryPharm Res2015321045542523101010.1007/s11095-014-1517-x181MattheolabakisGWongCCSunYAmellaCARichardsRConstantinidesPPRigasBPegylation improves the pharmacokinetics and bioavailability of small-molecule drugs hydrolyzable by esterases: a study of phospho-IbuprofenJ Pharmacol Exp Ther201435161662504751710.1124/jpet.114.217208182YangZWangJLuQXuJKobayashiYTakakuraTTakimotoAYoshiokaTLianCChenCZhangDZhangYLiSPEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primatesCancer Res200464667366781537498310.1158/0008-5472.CAN-04-1822183KellyGJKiaAFHassanFO'GradySMorganMPCreavenBSMcCleanSHarmeyJHDevocelleMPolymeric prodrug combination to exploit the therapeutic potential of antimicrobial peptides against cancer cellsOrg Biomol Chem2016149278862772273410.1039/c6ob01815g184SpinksCBZidanASKhanMAHabibMJFaustinoPJPharmaceutical characterization of novel tenofovir liposomal formulations for enhanced oral drug delivery: in vitro pharmaceutics and Caco-2 permeability investigationsClin Pharmacol2017929382826095210.2147/CPAA.S119875PMC5327912185DawidczykCMRussellLMHultzMSearsonPCTumor accumulation of liposomal doxorubicin in three murine models: Optimizing delivery efficiencyNanomedicine2017228[Epub ahead of print]10.1016/j.nano.2017.02.008PMC553825128254372186CernAMarcusDTropshaABarenholzYGoldblumANew drug candidates for liposomal delivery identified by computer modeling of liposomes’ remote loading and leakageJ Control Release201725218272821566910.1016/j.jconrel.2017.02.015187Abu LilaASIshidaTLiposomal Delivery Systems: Design Optimization and Current ApplicationsBiol Pharm Bull2017401102804994010.1248/bpb.b16-00624188LiHYuanDSunMPingQEffect of ligand density and PEG modification on octreotide-targeted liposome via somatostatin receptor in vitro and in vivoDrug Deliv2016233562722743258510.1080/10717544.2016.1209797189PazosESleepERubert PérezCMLeeSSTantakittiFStuppSINucleation and Growth of Ordered Arrays of Silver Nanoparticles on Peptide Nanofibers: Hybrid Nanostructures with Antimicrobial PropertiesJ Am Chem Soc20161385507102710359610.1021/jacs.6b01570PMC4859321190SandreschiSPirasAMBatoniGChielliniFPerspectives on polymeric nanostructures for the therapeutic application of antimicrobial peptidesNanomedicine (Lond)2016111729442734815510.2217/nnm-2016-0057191BrandelliANanostructures as promising tools for delivery of antimicrobial peptidesMini Rev Med Chem201212731412251255410.2174/138955712801264774192CocaASobrinoJMódolJSolerJMínguezAPlanaJDe la SierraA.A multicenter, parallel comparative study of the antihypertensive efficacy of once-daily lisinopril vs enalapril with 24-h ambulatory blood pressure monitoring in essential hypertensionJ Hum Hypertens199610837419140792193RengoFCanonicoV[Quinapril versus lisinopril in the treatment of essential hypertension in elderly patients with low blood renin]. [Article in Italian]Minerva Cardioangiol199644631359053816194BellissantENguyenPCGiudicelliJFPharmacokinetic-pharmacodynamic model relating lisinopril plasma concentrations to regional hemodynamic effects in healthy volunteersJ Cardiovasc Pharmacol199628470478887759610.1097/00005344-199609000-00018195ZornoffLAMatsubaraBBMatsubaraLSPaivaSATorneroMTSpadaroJEffects of lisinopril on experimental ischemia in rats. Influence of infarct sizeArq Bras Cardiol1999733593721075459010.1590/s0066-782x1999001000004196FosgerauKHoffmannTPeptide therapeutics: current status and future directionsDrug Discov Today201520122282545077110.1016/j.drudis.2014.10.003197VelemínskýJPlasma insulin response to glucose infusion in obese non-diabetic and diabetic subjectsHorm Metab Res19801265155700936610.1055/s-2007-999225198FarrarDTuffnellDJWestJWestHMContinuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetesCochrane Database Syst Rev20166CD00554210.1002/14651858.CD005542.pub3PMC856384727272351199AshkenaziAWexler-CohenYShaiYMultifaceted action of Fuzeon as virus-cell membrane fusion inhibitorBiochim Biophys Acta20111808235223582176267610.1016/j.bbamem.2011.06.020200Formal approval for FuzeonAIDS Patient Care STDS2004187361565988510.1089/apc.2004.18.736201HancockREChappleDSPeptide antibioticsAntimicrob Agents Chemother1999431317231034874510.1128/aac.43.6.1317PMC89271202KhmelIAMetlitskaiaAZFomenkoDEKatrukhaGSBasiukEIKurepinaNELipasovaVABezrukovVM[Microcins--new peptide antibiotics from enterobacteria and genetic control of their synthesis]. [Article in Russian]1999331131910330668203ShiWLChenXLWangLXGongZTLiSLiCLXieBBZhangWShiMLiCZhangYZSongXYCellular and molecular insight into the inhibition of primary root growth of Arabidopsis induced by peptaibols, a class of linear peptide antibiotics mainly produced by Trichoderma sppJ Exp Bot20166721912052685087910.1093/jxb/erw023PMC4809282204LeeTHHallKNAguilarMIAntimicrobial Peptide Structure and Mechanism of Action: A Focus on the Role of Membrane StructureCurr Top Med Chem20161625392613911210.2174/1568026615666150703121700205CenterMDInduction of Antitumor Response in Melanoma Patients Using the Antimicrobial Peptide LL37http://appswhoint/trialsearch/Trial2aspx?TrialID=NCT02225366. July 2015, updated on January 9, 2017; ClinicalTrials.gov206KościuczukEMLisowskiPJarczakJStrzałkowskaNJóźwikAHorbańczukJKrzyżewskiJZwierzchowskiLBagnickaECathelicidins: family of antimicrobial peptides. A reviewMol Biol Rep20123910957702306526410.1007/s11033-012-1997-xPMC3487008207TomasinsigLZanettiMThe cathelicidins—structure, function and evolutionCurr Protein Pept Sci2005623341563876610.2174/1389203053027520208ZanettiMCathelicidins, multifunctional peptides of the innate immunityJ Leukoc Biol20047539481296028010.1189/jlb.0403147209OrdonezSRAmarullahIHWubboltsRWVeldhuizenEJHaagsmanHPFungicidal mechanisms of cathelicidins LL-37 and CATH-2 revealed by live-cell imagingAntimicrob Agents Chemother2014582240482449235910.1128/AAC.01670-13PMC4023799210TomasinsigLDe ContiGSkerlavajBPiccininiRMazzilliMD'EsteFTossiAZanettiMBroad-spectrum activity against bacterial mastitis pathogens and activation of mammary epithelial cells support a protective role of neutrophil cathelicidins in bovine mastitisInfect Immun2010781781882010086210.1128/IAI.01090-09PMC2849419211ChuangCMMonieAWuAMaoCPHungCFTreatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancerHum Gene Ther200920303131927201310.1089/hum.2008.124PMC2855250212plc LBAaTI. A Phase I, Open-label, Multi-arm, Multi-centre, Multi-dose, Dose Escalation Study of LTX-315 as Monotherapy or in Combination With Either Ipilimumab or Pembrolizumab in Patients With Transdermally Accessible Tumourshttps://clinicaltrialsgov/ct2/show/NCT01986426?term=anticancer peptide&rank=102016213MelvinJALashuaLPKiedrowskiMRYangGDeslouchesBMontelaroRCBombergerJMSimultaneous Antibiofilm and Antiviral Activities of an Engineered Antimicrobial Peptide during Virus-Bacterium CoinfectionmSph2016110.1128/mSphere.00083-16PMC488888827303744